Taysha Gene Therapies, Inc. (TSHA) Balance Sheet
As of 2026-06-30 (10-Q), Taysha Gene Therapies, Inc. (TSHA) reported total assets of $470.4M, total liabilities of $83.2M and shareholders' equity of $387.3M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $455.4M. Long-term debt: $49.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TSHATaysha Gene Therapies, Inc.Follow TSHA — free
—
Price chart with a free account
- Market cap
- 1.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 251.3 | 149.1 | 87.9 | 143.9 | 139.0 | 319.8 | 455.4 | |
| Current assets | 257.9 | 159.6 | 96.4 | 149.9 | 142.1 | 324.6 | 461.4 | |
| Total assets | 258.9 | 214.0 | 126.3 | 172.7 | 160.4 | 343.3 | 470.4 | |
| Current liabilities | 7.1 | 51.7 | 62.8 | 36.8 | 26.2 | 26.6 | 26.0 | |
| Long-term debt | — | 37.2 | 38.0 | 40.5 | 43.9 | 50.1 | 49.3 | |
| Total liabilities | 7.6 | 118.6 | 125.3 | 97.8 | 88.8 | 96.4 | 83.2 | |
| Shareholders' equity | 251.3 | 95.4 | 0.9 | 74.9 | 71.5 | 246.9 | 387.3 |
USD millions · SEC XBRL
Taysha Gene Therapies, Inc. — questions
- How much cash does Taysha Gene Therapies, Inc. have?
- $455.4M in cash and cash equivalents as of 2026-06-30.
- How much debt does Taysha Gene Therapies, Inc. have?
- $49.3M of long-term debt as of 2026-06-30.
- What are Taysha Gene Therapies, Inc.'s total assets?
- $470.4M as of 2026-06-30.
- What is Taysha Gene Therapies, Inc.'s shareholders' equity?
- $387.3M as of 2026-06-30.
Every figure on this page comes from Taysha Gene Therapies, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.